Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
2019 · Blood Cancer Journal · 43 citations
https://doi.org/10.1038/s41408-019-0181-0
H
Heinz Ludwig
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
16
Citations
2
h-index
0
i10-index
Heinz Ludwig is an academic researcher. The author has contributed to research in topics: German Literature and Culture Studies & Solar and Space Plasma Dynamics & Corporate Governance and Management. The author has an h-index of 2, co-authored 8 publications.
Papers by this author
worksIMWG consensus on maintenance therapy in multiple myeloma
2012 · Blood · 194 citations
https://doi.org/10.1182/blood-2011-11-374249
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
2023 · The Lancet Oncology · 147 citations
https://doi.org/10.1016/s1470-2045(23)00159-6
MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents
2020 · Journal of Hematology & Oncology · 163 citations
https://doi.org/10.1186/s13045-020-01007-9
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
2023 · Blood Cancer Journal · 157 citations
https://doi.org/10.1038/s41408-023-00879-7
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
2020 · Leukemia · 149 citations
https://doi.org/10.1038/s41375-020-0876-z
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat